Pfizer Targets Generic Celebrex After Extending Patent
Pfizer Inc. on Tuesday received an 18-month extension for its patent for the arthritis medication Celebrex, and promptly sued five drug companies for patent infringement for attempting to produce generic versions...To view the full article, register now.
Already a subscriber? Click here to view full article